Nabriva Therapeutics has completed the acquisition of Zavante Therapeutics for $97.5m.
The acquisition will add the target company’s CONTEPO™ drug, which is indicated for the treatment of complicated urinary tract infections (cUTIs), to Nabriva’s late-stage anti-infective portfolio.
Based in Ireland, Nabriva is a clinical-stage biopharmaceutical company focused on the development of novel antibiotics, while Zavante is a US-based biopharmaceutical company involved in the development of novel therapies.
The acquisition enables the acquirer company to strengthen its position in the antibiotics market in the US.
Latham & Watkins has been appointed as legal adviser to Zavante Therapeutics for the transaction.
Sangamo Therapeutics has signed an agreement to acquire TxCell for €72m ($83.71m).
Sangamo will file a cash tender offer to acquire all outstanding shares of TxCell, priced at €2.58 ($2.9) a share.
The transaction is expected to be closed in the last quarter of 2018, subject to customary closing conditions.
Based in the US, Sangamo Therapeutics is a clinical-stage product development company, while TxCell is a cellular immunotherapy platforms developer based in France.
The transaction will enable the acquirer company to use the target company’s CAR-Treg platform and pipeline for the treatment of autoimmune diseases such as Crohn’s disease and multiple sclerosis.
Ryboquin has completed the acquisition of Nanogenic Solutions.
The target company will be named Nanogenics Limited, following the acquisition.
Ryboquin is funding the acquisition through €4.45m ($5.17m) raised in a third financing round participated by new and existing investors.
Based in the UK, Ryboquin is a pharmaceutical company that develops oncology therapies, while Nanogenic Solutions, also based in the UK, is a developer of LipTide, an artificial virus that acts as a vector for gene therapy.
The transaction is expected to enable the acquirer company to revolutionise gene therapy.